Skip to main content
Fig. 3 | Journal of Biological Engineering

Fig. 3

From: An innovative lab-scale production for a novel therapeutic DNA vaccine candidate against rheumatoid arthritis

Fig. 3

Purity analysis of the final plasmid products. a Analysis of the final plasmid using 0.8% agarose gel electrophoresis (5 V/cm, 35 min). Lane 1: plasmid purified via anion exchange column chromatography (AEC). Lane 2: plasmid purified using a commercial kit. Lane 3: plasmid purified using a combination of PEG/MgCl2 precipitation and Triton X-114. OC: open circle; SC: supercoiled circle. b The amplification curves include gene-positive samples assessed with three duplicates per sample using real-time quantitative PCR (RT-qPCR). c Analysis of plasmid forms after purifying the pcDNA-CCOL2A1 vaccine via high-performance liquid chromatography (HPLC)

Back to article page